GlassScriptPhysician profile
Rose Pierson
NPI 1184739591
$16,018.02
in general payments reported to CMS, 2019-2025
30 companies · $3,653 in 2025
The $3,653 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,326 · 2022: $3,563 · 2023: $2,742 · 2024: $2,734 · 2025: $3,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,010 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,009.57 |
| Education | $119.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,894.86 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,729.13 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $1,773.78 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,551.12 | 2021-2025 | Dupixent |
| Amgen INC. | $771.05 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $715.59 | 2021-2025 | Xolair |
| Leo Pharma INC. | $603.12 | 2022-2025 | Adbry |
| Csl Behring | $479.59 | 2024-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $395.22 | 2021-2025 | |
| Optinose US, INC. | $359.29 | 2021-2025 | |
| Grifols USA, LLC | $315.39 | 2021-2023 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $248.36 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $212.72 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.84 | 2021-2025 | Cuvitru |
| Covis Pharma Gmbh | $113.77 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $99.89 | 2023-2025 | Ayvakit |
| Verona Pharma, INC. | $90.31 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $84.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.31 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Ars Pharmaceuticals Operations, INC. | $69.75 | 2025 | Neffy |
| Incyte Corporation | $58.41 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.56 | 2021 | |
| Mylan Specialty L.P. | $39.70 | 2024 | Yupelri |
| Azurity Pharmaceuticals, INC. | $32.37 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $29.40 | 2021-2023 | |
| Cycle Pharmaceuticals INC | $21.79 | 2025 | Sajazir |
| Octapharma USA, INC. | $19.22 | 2025 | Panzyga |
| Pharming Healthcare, INC. | $18.78 | 2024 | Ruconest |
| Kaleo, INC. | $18.04 | 2022 | |
| Galderma Laboratories, L.P. | $15.67 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Pierson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.